Dr. Sanjay Gupta on medical marijuana: We are in an age of wisdom, but also an age of foolishness
When we released “Weed” in 2013, few people had ever heard of cannabidiol, or CBD. Now, two-thirds of Americans are familiar with the compound, and 1 in 7 have tried it. Most of the country, 93%, are in favor of medical marijuana and hemp-derived CBD itself, which has less than 0.3% THC, has been legalized in every state.It’s not just public perception. The science over the last six years has grown by leaps and bounds, as well. Epidiolex, a pharmaceutical-grade CBD oil, went through clinical trials and is being prescribed for thousands of patients with seizures. The founder of GW Pharmaceuticals, the maker of Epidiolex, told me they are now developing cannabis medications for everything from autism to anxiety.
Stories you may be interested in
Three Key Voices in the Medical Marijuana Industry
As medical marijuana programs continue to expand throughout the United States, it is important to recognize some of the key voices throughout the industry that got us here. These individuals range from researches to physicians and even to patients who started their own advocacy group. Keep reading to learn about just three of the many…
Read More 
Unstructured EHR data more useful for predictive analytics, study shows
A new report in the Journal of the American Medical Informatics Association has shown that real-world data contained in unstructured narratives has big predictive value when it comes to clinical research. WHY IT MATTERSWhile structured clinical notes in the electronic health record have obvious value, the research in JAMIA suggests that real-world data captured in unstructured notes…
Read More 
Former Detroit Lions players announce partnership with Harvard to study marijuana
Former Detroit Lions football players Calvin Johnson and Robert Sims are expanding their emerging cannabis enterprise into the field of medicine. The pair announced an agreement Thursday with the International Phytomedicines and Medical Cannabis Institute at Harvard University, which is researching the benefits of medical marijuana and looking at the best ways to deliver cannabis-based…
Read More 
New Feature Updates
It’s a new feature alert! At Arfinn Med we always work to make sure we are the industry leading software platform and EMR for medical cannabis providers and clinics. Keeping with that sentiment, we’ve recently updated two features that have been very popular with Arfinn Med users. Those are the customizable consent and confirmation page…
Read More 
Cannabis and Mental Health: Social Anxiety Disorder
Social anxiety may sound like something we all experience at times in life, and that is true. It is natural for a person to feel nervous or anxious in situations like being alone in a new place or going on a first date. But for those living with social anxiety disorder, those instances of anxiety…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More